United Kingdom (UK)
Recombinant monoclonal antibody to Acrolein-modified protein. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 5F6.
Alternative Name(s) of Target: Acrolein modified protein; ACR-P; ACRL
Immunogen: The original antibody was generated by immunizing BALB/c mice with an acrolein-treated keyhole limpet hemocyanin (KLH).
Specificity: This antibody is specific for acrolein-modified proteins. Protein modification by acrolein is largely attributed to the formation of acrolein-lysine and acrolein-histidine adducts that possess a carbonyl function. While the antibody has been raised against acrolein-modified KLH, it has been shown to recognize both acrolein-modified BSA and oxidized LDL.
Application Notes: A direct ELISA examined the immunoreactivity of this antibody to aldehyde-treated proteins. It was scarcely inhibited by Na-acetyl-Nim-propanal-histidine and significantly inhibited by Na-acetyl-FDP-lysine, indicating that FDP-lysine (Nε-(3-formyl-3,4-dehydropiperidino)lysine) is an epitope. This antibody was also used for immunohistochemistry (IHC) detection of protein-bound acrolein in fatty streak lesions of arterial tissue (Uchida et al., 1998; PMID: 9560197). This antibody was used in flow cytometry (FC) to detect protein-bound acrolein in activated human T cells (Fonseca et al., 2001; PMID: 11342443). A novel pyridinium-type lysine adduct, Nϵ-(3-methyl-pyridinium)lysine (MP-lysine), was investigated and found to be a major epitope of this antibody (Furuhata et al., 2003; PMID: 14504272). This antibody was used for IHC to detect oxidative stress in the testis of rats (Iuchi et al., 2004; PMID: 14673659). This antibody was used for WB to detect acrolein modification of apoE3-NT (Tamamizu-Kato et al., 2007; PMID: 17580963).
Antibody first published in:
Uchida et al. Protein-bound acrolein: potential markers for oxidative stress. Proc Natl Acad Sci USA. 1998 Apr 28;95(9):4882-7. doi: 10.1073/pnas.95.9.4882 PMID:9560197
Note on publication:
The original publication describes the development of the antibody, which recognizes protein-bound acrolein, a potential marker of oxidative stress and long-term protein damage in aging, atherosclerosis, and diabetes.